Revenue Analysis – Global Type 2 Diabetes Mellitus Therapeutics Market Till 2021

1
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021- Strong Pipeline and
Expanding Treatment Population to Encourage
Robust Growth
Published on 03 July, 2015 Number of pages
179 Single User Price 4995
Over the 20142021 forecast period, the Global
T2DM Market is expected to increase in value at a
CAGR of 7.5 from 23.5 Billion to 39.0 Billion.
2
Summary of the ReportType 2 Diabetes Mellitus
(T2DM) is a metabolic disease characterized by
chronic hyperglycemia (high blood glucose
levels). Global prevalence has risen rapidly in
the past several decades, particularly in line
with obesity. This has been attributed to a range
of factors, including economic development,
increasing urbanization, aging populations, and
changes in lifestyle patterns such as reduced
levels of physical activity and consumption of
higher-calorie diets. This has led to strong
commercial interest in the development of T2DM
therapeutics. The current market is large and
diverse, comprising several drug classes,
including generic and branded drugs. Owing to the
range of therapeutic options available, the
treatment algorithm is complex. However, current
treatment regimens are often associated with
limited long-term efficacy, complex and
inconvenient dosing regimens, and undesirable
side effects such as weight gain and hypoglycemia
(low blood glucose levels).
Click Here To Check Complete Report
3

• Scope of the Report
• Metformin monotherapy will remain the first-line
  pharmacotherapy for T2DM.
• The emergence of several new drug classes over
  the past decade, namely the Glucagon-Like
  Peptide-1 (GLP-1) receptor agonists, Dipeptidyl
  Peptidase 4 (DPP-4) inhibitors, and
  SodiumGlucose Cotransporter 2 (SGLT-2)
  inhibitors, has led to considerable market
  growth.
• Which products lead these drug classes and what
  threats do they face from the pipeline?
• How will the continued uptake of newer drug
  classes impact established drug classes such as
  the sulfonylureas and thiazolidinediones?
• Will recently approved insulin therapies such as
  Tresiba (insulin degludec) and Toujeo (insulin
  glargine) be able to capture a significant
  portion of Lantus market share?
• The pipeline is large and highly innovative,
  comprising a range of molecule types and
  molecular targets.
• Which late-stage pipeline molecules show the most
  promise and how will they impact the treatment
  algorithm over the forecast period?
• Over the 20142021 forecast period, the global
  T2DM market is expected to increase in value at a
  CAGR of 7.5 from 23.5 billion to 39.0 billion.

Download Sample Brochure
4

• Reasons to Buy
• Understand the clinical context of the T2DM
  indication and the global burden of the disease
  by considering epidemiology, symptoms, etiology,
  pathophysiology, co-morbidities and
  complications, disease classification, disease
  prognosis, and treatment options
• Appreciate the current T2DM marketed products
  landscape, including the dominant therapeutic
  strategies, products, and companies, and
  recognize gaps within the market and areas of
  unmet need
• Recognize the late-stage pipeline molecules that
  have demonstrated strong therapeutic potential in
  T2DM by examining clinical trial data and
  multi-scenario product forecast projections
• Consider market opportunities and potential risks
  by examining trends in T2DM clinical trial size,
  duration, and failure rate by phase of
  development, molecule type, and molecular target
• Discern variances in treatment usage patterns,
  annual therapy costs, and market growth
  projections for the US, Canada, the UK, France,
  Germany, Italy, Spain, and Japan
• Discover how strategic consolidations have shaped
  the current T2DM pipeline and marketed products
  landscapes

Make an Inquiry Before Buying
5
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021- Strong Pipeline and
Expanding Treatment Population to Encourage
Robust Growth
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Type 2 Diabetes Mellitus Therapeutics Market
are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Type 2 Diabetes
Mellitus Therapeutics Market Report